Form 4 for PTCT PTC THERAPEUTICS, INC.
Accepted 2026-01-06 00:00:00 ET · period of report 2026-01-02 · accession 0001578852-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-01-06 | 2026-01-05 | PTCT | Boulding Mark Elliott | EVP AND CLO | S - Sale+OE | $75.55 | -2,266 | 120.9K | -2% | -$171.2K |
| D | 2026-01-06 | 2026-01-02 | PTCT | Boulding Mark Elliott | EVP AND CLO | A - Grant | $0.00 | +17.0K | 120.9K | +16% | $0 |
| D | 2026-01-06 | 2026-01-05 | PTCT | Boulding Mark Elliott | EVP AND CLO | M - OptEx | $39.42 | +2,266 | 123.2K | +2% | +$89.3K |
| D | 2026-01-06 | 2026-01-02 | PTCT | Boulding Mark Elliott | EVP AND CLO | A - Grant | $0.00 | +42.5K | 42.5K | New | $0 |
| D | 2026-01-06 | 2026-01-05 | PTCT | Boulding Mark Elliott | EVP AND CLO | M - OptEx | $0.00 | -2,266 | 9,063 | -20% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-05 | S | D | 1,123 | $74.92 | 122,044 | D | — | — | (F3) This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $74.55 to $75.27 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. |
| 2 | Common | Common Stock | 2026-01-05 | S | D | 1,035 | $76.10 | 121,009 | D | — | — | (F4) This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $75.58 to $76.42 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Stock | 2026-01-02 | A | A | 17,000 | $0.00 | 120,901 | D | — | — | (F1) Restricted stock units granted on January 2, 2026 that vest in four equal installments over four years, commencing on January 2, 2027. |
| 4 | Common | Common Stock | 2026-01-05 | S | D | 108 | $76.79 | 120,901 | D | — | — | (F5) This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $76.75 to $76.81 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. |
| 5 | Common | Common Stock | 2026-01-05 | M | A | 2,266 | $39.42 | 123,167 | D | — | — | |
| 6 | Derivative | Stock Option (Right to Buy) | 2026-01-02 | A | A | 42,500 | $0.00 | 42,500 | D | $76.74 · — to 2036-01-01 | 42,500 Common Stock | (F6) This option was granted on January 2, 2026, and vests over four years, with 25% of the shares underlying the option vesting on January 2, 2027, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 2, 2027. |
| 7 | Derivative | Stock Option (Right to Buy) | 2026-01-05 | M | D | 2,266 | $0.00 | 9,063 | D | $39.42 · — to 2033-01-04 | 2,266 Common Stock | (F7) This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024. |